溪砾科技（深圳）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders 2024-07-26 21:00
CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A 2024-06-19 21:00
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals 2024-06-17 22:00
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies 2023-02-08 22:00
ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit 2022-12-08 23:00
ReviR Therapeutics Expands Research Team by Appointing Dr. Sridhar Narayan as Head of Medicinal Chemistry 2022-10-24 22:00
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer 2022-07-01 22:00
ReviR Therapeutics Announces Dr. David Dornan as Independent Board Director 2022-04-28 22:00
1